Drug lookup | Fillwise

FLUVASTATIN SODIUM

Form:

5 of 5 products shown

3 general benefit · 2 not a benefit

Other products in the same Health Canada class (C10A, C10AA) — coverage varies; not interchangeable

Atorvastatin (Lipitor): general benefit
Lovastatin (Mevacor): general benefit, Not a benefit
Pravastatin (Pravachol): general benefit, Not a benefit
Rosuvastatin (Crestor): general benefit
Simvastatin (Zocor): general benefit, Not a benefit
Bezafibrate (Bezalip): general benefit

9 more in the class list below

Teva-Fluvastatin · DIN 02299224 · 20mg · capsule

General benefitMarketed · checked 2026-09-02

StatusGeneral benefit

Write on scriptno code needed

Patient paysPatient pays: program not supplied; amount cannot be determined.

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

1 brand, same coverage

Teva-Fluvastatin · DIN 02299224 Manufacturer: Teva Canada Limited; listing date 2013-02-28 Health Canada: Marketed since 2012-12-11 · brand TEVA-FLUVASTATIN · ATC C10AA04 FLUVASTATIN · form Capsule · route Oral · ingredients FLUVASTATIN (FLUVASTATIN SODIUM) 20 MG · company Teva canada limited · schedule Prescription

Check this DIN again · Health Canada product record

Teva-Fluvastatin: Formulary list price $0.6882/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.6882 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=78461 · Verify on the e-Formulary ↗ (DIN 02299224)

Source record

DIN 02299224: Teva-Fluvastatin Raw flags: chronicUseMed=Y, sec3=Y Item: 240600024; group id 304; item number 0664; lccId None; manufacturer id TEV Source form: Cap; strength: 20mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.6882; ministry $0.6882 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02299224 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=78461

Interchangeable products

Lescol · DIN 02061562 · not recorded

Shortage status: resolved shortage (ended 2024-04-24); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02299224

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Teva-Fluvastatin · DIN 02299232 · 40mg · capsule

General benefitMarketed · checked 2026-09-19

StatusGeneral benefit

Write on scriptno code needed

Patient paysPatient pays: program not supplied; amount cannot be determined.

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

1 brand, same coverage

Teva-Fluvastatin · DIN 02299232 Manufacturer: Teva Canada Limited; listing date 2013-02-28 Health Canada: Marketed since 2012-12-11 · brand TEVA-FLUVASTATIN · ATC C10AA04 FLUVASTATIN · form Capsule · route Oral · ingredients FLUVASTATIN (FLUVASTATIN SODIUM) 40 MG · company Teva canada limited · schedule Prescription

Check this DIN again · Health Canada product record

Teva-Fluvastatin: Formulary list price $0.9671/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.9671 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Source record

DIN 02299232: Teva-Fluvastatin Raw flags: chronicUseMed=Y, sec3=Y Item: 240600025; group id 304; item number 0665; lccId None; manufacturer id TEV Source form: Cap; strength: 40mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.9671; ministry $0.9671 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02299232 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=78462

Interchangeable products

Lescol · DIN 02061570 · not recorded

Shortage status: active shortage (reported 2026-06-03, estimated to end 2026-08-31, last updated 2026-06-04); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02299232

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Lescol XL · DIN 02250527 · 80mg · extended release tablet

General benefit; Health Canada lists this DIN as Cancelled post market since 2021-06-14 — choose a marketed DIN from the same-category list.Discontinued 2021-06-14 · checked 2026-09-02

StatusGeneral benefit; Health Canada lists this DIN as Cancelled post market since 2021-06-14 — choose a marketed DIN from the same-category list.

Write on scriptno code needed; Health Canada lists this DIN as Cancelled post market since 2021-06-14 — choose a marketed DIN from the same-category list.

Patient paysPatient pays: program not supplied; amount cannot be determined.

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

No interchangeable product listed in the Ontario extract

Lescol XL · DIN 02250527 Manufacturer: Novartis Pharma Canada Inc.; listing date 2005-02-22 Health Canada: Cancelled post market since 2021-06-14 · brand LESCOL XL · ATC C10AA04 FLUVASTATIN · form Tablet (extended-release) · route Oral · ingredients FLUVASTATIN (FLUVASTATIN SODIUM) 80 MG · company Novartis pharmaceuticals canada inc · schedule Prescription

Check this DIN again · Health Canada product record

Lescol XL: Formulary list price $1.6225/unit (unit not stated in source; not the patient's cost)

Ministry pays: $1.6225 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=73534 · Verify on the e-Formulary ↗ (DIN 02250527)

Source record

DIN 02250527: Lescol XL Raw flags: chronicUseMed=Y, sec3=Y Item: 240600050; group id 304; item number 0666; lccId None; manufacturer id NOV Source form: ER Tab; strength: 80mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $1.6225; ministry $1.6225 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02250527 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=73534

Shortage status: discontinued (2020-04-03, reported by NOVARTIS PHARMACEUTICALS CANADA INC); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02250527

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Health Canada lists this DIN as Cancelled post market since 2021-06-14 — choose a marketed DIN from the same-category list.

Lescol · DIN 02061562 · 20mg · capsule

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2018-09-21 — choose a marketed DIN from the same-category list.Discontinued 2018-09-21 · checked 2026-09-02

StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2018-09-21 — choose a marketed DIN from the same-category list.

Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 2018-09-21 — choose a marketed DIN from the same-category list.

Patient paysPatient pays: program not supplied; amount cannot be determined.

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

1 brand, same coverage

Lescol · DIN 02061562 Manufacturer: Novartis Pharma Canada Inc.; listing date 1996-10-01 Health Canada: Cancelled post market since 2018-09-21 · brand LESCOL 20MG · ATC C10AA04 FLUVASTATIN · form Capsule · route Oral · ingredients FLUVASTATIN (FLUVASTATIN SODIUM) 20 MG · company Novartis pharmaceuticals canada inc · schedule Prescription

Check this DIN again · Health Canada product record

Lescol: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=15820 · Verify on the e-Formulary ↗ (DIN 02061562)

Source record

DIN 02061562: Lescol Raw flags: chronicUseMed=Y, notABenefit=Y, sec3=Y Item: 240600024; group id 304; item number 0664; lccId None; manufacturer id NOV Source form: Cap; strength: 20mg Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02061562 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=15820

Interchangeable products

Teva-Fluvastatin · DIN 02299224 · $0.6882

Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02061562

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Health Canada lists this DIN as Cancelled post market since 2018-09-21 — choose a marketed DIN from the same-category list.

Lescol · DIN 02061570 · 40mg · capsule

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2018-09-21 — choose a marketed DIN from the same-category list.Discontinued 2018-09-21 · checked 2026-09-02

StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2018-09-21 — choose a marketed DIN from the same-category list.

Patient paysPatient pays: program not supplied; amount cannot be determined.

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

1 brand, same coverage

Lescol · DIN 02061570 Manufacturer: Novartis Pharma Canada Inc.; listing date 1996-10-01 Health Canada: Cancelled post market since 2018-09-21 · brand LESCOL 40MG · ATC C10AA04 FLUVASTATIN · form Capsule · route Oral · ingredients FLUVASTATIN (FLUVASTATIN SODIUM) 40 MG · company Novartis pharmaceuticals canada inc · schedule Prescription

Check this DIN again · Health Canada product record

Lescol: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=15821 · Verify on the e-Formulary ↗ (DIN 02061570)

Source record

DIN 02061570: Lescol Raw flags: chronicUseMed=Y, notABenefit=Y, sec3=Y Item: 240600025; group id 304; item number 0665; lccId None; manufacturer id NOV Source form: Cap; strength: 40mg Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02061570 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=15821

Interchangeable products

Teva-Fluvastatin · DIN 02299232 · $0.9671

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Health Canada lists this DIN as Cancelled post market since 2018-09-21 — choose a marketed DIN from the same-category list.

Other drugs in the same formulary class (24:06 Antilipemic Drugs) and how they are covered

Matched class: 24:06 Antilipemic Drugs

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: AMLODIPINE BESYLATE & ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM, BEZAFIBRATE, ROSUVASTATIN CALCIUM Some products covered without a code (check the product listing): CHOLESTYRAMINE RESIN, COLESEVELAM HYDROCHLORIDE, FENOFIBRATE, GEMFIBROZIL, LOVASTATIN, PRAVASTATIN SODIUM, SIMVASTATIN 24:00 CARDIOVASCULAR DRUGS

INCLISIRAN

· 1 products · Limited Use, codes 732 · strengths: 284mg/1.5mL · Inj Sol-1.5mL Pref Syr Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 24:00 24:06 Antilipemic Drugs

ATORVASTATIN CALCIUM

· 99 products · General benefit · strengths: 10mg, 20mg, 40mg, 80mg · Tab

LOVASTATIN

· 4 products · Listed, not a benefit (2), General benefit (2) · strengths: 20mg, 40mg · Tab

PRAVASTATIN SODIUM

· 57 products · Listed, not a benefit (3), General benefit (54) · strengths: 10mg, 20mg, 40mg · Tab

ROSUVASTATIN CALCIUM

· 80 products · General benefit · strengths: 5mg, 10mg, 20mg, 40mg · Tab

SIMVASTATIN

· 73 products · Listed, not a benefit (5), General benefit (68) · strengths: 5mg, 10mg, 20mg, 40mg, 80mg · Tab

BEZAFIBRATE

· 2 products · General benefit · strengths: 400mg · SR Tab

CHOLESTYRAMINE RESIN

· 4 products · Listed, not a benefit (1), General benefit (3) · strengths: · Oral Pd-Pouch Pk

COLESEVELAM HYDROCHLORIDE

· 3 products · General benefit (2), Temporary benefit (1) · strengths: 625mg · Tab

FENOFIBRATE

· 16 products · Listed, not a benefit (2), General benefit (9), Off-Formulary Interchangeable, not an ODB benefit (5) · strengths: 100mg, 67mg, 200mg, 160mg, 48mg, 145mg · Cap, Tab

GEMFIBROZIL

· 6 products · Listed, not a benefit (1), General benefit (2), Off-Formulary Interchangeable, not an ODB benefit (3) · strengths: 300mg, 600mg · Cap, Tab

EVOLOCUMAB

· 1 products · Limited Use, codes 527, 737 · strengths: 140mg/mL · Inj Sol-Pref Syr Autoinj Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 24:06 and 4 more

Full class listing Related classes: 24:04 Cardiac Drugs, 24:08 Hypotensive Drugs (For Diuretics See 40:28), 24:12 Vasodilating Drugs, 24:32 Renin-Angiotensin Aldosterone Inhibitors Same formulary class, not same indication: class membership alone does not establish equivalent uses.

What the Health Canada label says it is for

1. Indications Therapy with lipid-altering agents should be considered a component of multiple risk factor intervention in those individuals at increased risk for atherosclerotic vascular disease due to hypercholesterolemia. TEVA-FLUVASTATIN (fluvastatin sodium) should be used in addition to a diet restricted in saturated fat and cholesterol when the response to diet and other non- pharmacological measures alone has been inadequate. Hypercholesterolemia and Mixed Hyperlipidemia Adults TEVA-FLUVASTATIN is indicated as an adjunct to diet (at least equivalent to the Adult Treatment Panel III (ATP III TLC diet)) in the treatment of elevated total cholesterol (Total-C), LDL-C and triglycerides (TG) and Apo B levels in patients with primary hypercholesterolemia and mixed hyperlipidemia (Fredrickson Type IIa and IIb) whose response to dietary restriction of saturated fat and cholesterol and other non-pharmacological measures has not been adequate. Therapy with lipid-altering agents should be considered only after secondary causes for hyperlipidemia such as poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinemias, obstructive liver disease, other medica… https://pdf.hres.ca/dpd_pm/00081221.PDF PM date: 2025-07-24 Source product: TEVA-FLUVASTATIN; DIN 02299224; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Availability

Teva-Fluvastatin · DIN 02299232 Shortage status: active shortage (reported 2026-06-03, estimated to end 2026-08-31, last updated 2026-06-04); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02299232

Check this DIN again

Lescol XL · DIN 02250527 Shortage status: discontinued (2020-04-03, reported by NOVARTIS PHARMACEUTICALS CANADA INC); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02250527

Check this DIN again

Other review policies

For Lescol: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.

For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy

Compassionate Review Policy: source quote

Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.

Ontario source; updated September 15, 2026

For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)

Case-by-Case Review (cancer drugs): source quote

Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.

Ontario source; updated September 15, 2026